Cost of illness in psoriasis patients on Bath PUVA therapy versus Methotrexate

Swapna Satheendran, Anantha Naik Nagappa, Rajan M Surulivel, Sathish Pai

Research output: Contribution to journalArticle

Abstract

Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients. Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done. Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits. Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.

Original languageEnglish
Pages (from-to)59-62
Number of pages4
JournalJournal of Applied Pharmaceutical Science
Volume6
Issue number11
DOIs
Publication statusPublished - 2016

Fingerprint

PUVA Therapy
Cost of Illness
Baths
Psoriasis
Methotrexate
Costs and Cost Analysis
Phototherapy
Health Care Costs
Medical Records
Hospitalization

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{0af267862cfa4576ac79470203213e50,
title = "Cost of illness in psoriasis patients on Bath PUVA therapy versus Methotrexate",
abstract = "Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients. Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done. Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits. Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.",
author = "Swapna Satheendran and Nagappa, {Anantha Naik} and Surulivel, {Rajan M} and Sathish Pai",
year = "2016",
doi = "10.7324/JAPS.2016.601109",
language = "English",
volume = "6",
pages = "59--62",
journal = "Journal of Applied Pharmaceutical Science",
issn = "2231-3354",
publisher = "MediPoeia",
number = "11",

}

Cost of illness in psoriasis patients on Bath PUVA therapy versus Methotrexate. / Satheendran, Swapna; Nagappa, Anantha Naik; Surulivel, Rajan M; Pai, Sathish.

In: Journal of Applied Pharmaceutical Science, Vol. 6, No. 11, 2016, p. 59-62.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost of illness in psoriasis patients on Bath PUVA therapy versus Methotrexate

AU - Satheendran, Swapna

AU - Nagappa, Anantha Naik

AU - Surulivel, Rajan M

AU - Pai, Sathish

PY - 2016

Y1 - 2016

N2 - Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients. Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done. Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits. Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.

AB - Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients. Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done. Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits. Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.

UR - http://www.scopus.com/inward/record.url?scp=85009237734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009237734&partnerID=8YFLogxK

U2 - 10.7324/JAPS.2016.601109

DO - 10.7324/JAPS.2016.601109

M3 - Article

VL - 6

SP - 59

EP - 62

JO - Journal of Applied Pharmaceutical Science

JF - Journal of Applied Pharmaceutical Science

SN - 2231-3354

IS - 11

ER -